Birgitte
Birgitte Andersen, Bagsvaerd DK
Patent application number | Description | Published |
---|---|---|
20100016230 | Treatment Of Inflammatory Bowel Diseases With Mammal Beta Defensins - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 01-21-2010 |
20100016231 | Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins - The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins. | 01-21-2010 |
20100016232 | Treatment Of Inflammatory Diseases With Mammal Beta Defensins - The present invention relates to suppression of TNF-alpha activity with mammal beta defensins, which has utility in the treatment of pathological conditions associated with tumor necrosis factor alpha. | 01-21-2010 |
20110251139 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH MAMMAL BETA DEFENSINS - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 10-13-2011 |
20120309678 | Treatment of Inflammatory Bowel Diseases With Mammal Beta Defensins - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 12-06-2012 |
20120309686 | Treatment of Rheumatoid Arthritis With Mammal Beta Defensins - The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins. | 12-06-2012 |
20130172235 | ORAL TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin. | 07-04-2013 |
20140135258 | Treatment of Inflammatory Bowel Diseases with Mammal Beta Defensins - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 05-15-2014 |
20140213521 | Oral Treatment of Inflammatory Bowel Disease - The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin. | 07-31-2014 |
Birgitte Andersen, Maaloev DK
Patent application number | Description | Published |
---|---|---|
20130190232 | N-TERMINAL MODIFIED FGF21 COMPOUNDS - Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). | 07-25-2013 |
20130252884 | FGF21 ANALOGUES AND DERIVATIVES - Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described. | 09-26-2013 |
Birgitte Bang-Madsen, Norre Snede DK
Patent application number | Description | Published |
---|---|---|
20110064783 | Flavor Impregnation Of A Chewing Gum Core - A method of adding flavor to a chewing gum core of a chewing gum, the chewing gum including active pharmaceutical ingredients, the method of adding flavor to a chewing gum core including the steps of: providing a chewing gum core including gum base, impregnating the chewing gum core by adding at least one dose of liquid flavor mixture onto the chewing gum core prior to any optional coating of the chewing gum core, wherein at least the flavor in the liquid flavor mixture has affinity for the gum base in the chewing gum core. | 03-17-2011 |
Birgitte Lygren, Kolbotn NO
Patent application number | Description | Published |
---|---|---|
20150133510 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS - The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP185) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl)amine structure. | 05-14-2015 |
Birgitte Maibom, Beecroft Nsw AU
Patent application number | Description | Published |
---|---|---|
20140067856 | SYSTEMS AND METHODS FOR FACILITATING DIAGNOSIS AND PRODUCT IDENTIFICATION FOR PATIENTS REQUIRING CONTINENCE PRODUCTS - Systems and methods for facilitating diagnosis and product identification for patients requiring continence products. Embodiments of the invention have been particularly developed there by to provide a software application (for example an iOS or Android application) thereby to assist a clinician and/or patient in identifying appropriate continence products for a given set of patient requirements. While some embodiments will be described herein with particular reference to that application, it will be appreciated that the invention is not limited to such a field of use, and is applicable in broader contexts. | 03-06-2014 |
Birgitte Møllgaard, Virum DK
Patent application number | Description | Published |
---|---|---|
20140086991 | Controlled Agglomeration - A process for the preparation of a particu 1265 late material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5 DEG C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material. | 03-27-2014 |
Birgitte Nauntofte, Charlottenlund DK
Patent application number | Description | Published |
---|---|---|
20090169488 | Acidic solid oral compositons without erosive potential in saliva and method for determining erosive potential in saliva - Acidic oral compositions having calcium contents and effective pH-values in the area indicated by grey tone in FIG. | 07-02-2009 |
20140121274 | ACIDIC SOLID ORAL COMPOSITIONS WITHOUT EROSIVE POTENTIAL IN SALIVA AND METHOD FOR DETERMINING EROSIVE POTENTIAL IN SALIVA - Acidic oral compositions having calcium contents and effective pH-values in the area indicated by grey-tone in FIG. | 05-01-2014 |
Birgitte Nielsen, Oslo NO
Patent application number | Description | Published |
---|---|---|
20110274336 | OPTIMIZING THE INITIALIZATION AND CONVERGENCE OF ACTIVE CONTOURS FOR SEGMENTATION OF CELL NUCLEI IN HISTOLOGICAL SECTIONS - A computer-implemented segmentation method is used to process an image representing a plurality of nuclei. The method is implemented in a computer having a processor and a physical memory. A set of instructions are provided to the processor the physical memory of the computer. The processor is configured by executing the set of instructions in the physical memory so as to automatically segment the image by: thresholding a grey-scale image to create a black and white image; identifying objects in the black and white image and removing objects failing to meet predetermined criteria; extracting objects; and applying an edge detector on the segmented image to identify the edges of the nuclei. Overlapping nuclei are split to improve results. | 11-10-2011 |
Birgitte Rönnow, Copenhagen K DK
Patent application number | Description | Published |
---|---|---|
20110099892 | MICROORGANISM EXPRESSING ALDOSE-1-EPIMERASE - A transformed microorganism capable of converting an aldopentose to a ketopentose at a higher rate than the equivalent microorganism prior to transformation. | 05-05-2011 |
20140099720 | MICROORGANISM EXPRESSING XYLOSE ISOMERASE - The present invention relates to a transformed microorganism capable of (a) a higher xylose isomerase activity than the equivalent microorganism prior to transformation; and/or (b) a higher growth rate in or on a growth medium comprising xylose than the equivalent microorganism prior to transformation; and/or (c) a faster metabolism of xylose than the equivalent microorganism prior to transformation; and/or (d) a higher production of ethanol when grown anaerobically on xylose as the carbon source than the equivalent microorganism prior to transformation. | 04-10-2014 |
Birgitte Rönnow, Copenhagenk DK
Patent application number | Description | Published |
---|---|---|
20110244525 | MICROORGANISM EXPRESSING XYLOSE ISOMERASE - The present invention relates to a transformed microorganism capable of (a) a higher xylose isomerase activity than the equivalent microorganism prior to transformation; and/or (b) a higher growth rate in or on a growth medium comprising xylose than the equivalent microorganism prior to transformation; and/or (c) a faster metabolism of xylose than the equivalent microorganism prior to transformation; and/or (d) a higher production of ethanol when grown anaerobically on xylose as the carbon source than the equivalent microorganism prior to transformation. | 10-06-2011 |
Birgitte Rönnow, Copenhagen K DK
Patent application number | Description | Published |
---|---|---|
20110099892 | MICROORGANISM EXPRESSING ALDOSE-1-EPIMERASE - A transformed microorganism capable of converting an aldopentose to a ketopentose at a higher rate than the equivalent microorganism prior to transformation. | 05-05-2011 |
Birgitte Skadhauge, Bikerod DK
Patent application number | Description | Published |
---|---|---|
20150218498 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE - According to the invention, there is provided null-LOX-1 barley and plant products produced thereof, such as malt manufactured by using barley kernels defective in synthesis of the fatty acid-converting enzyme lipoxygenase-1. Said enzyme accounts for the principal activity related to conversion of linoleic acid into 9-hydroperoxy octadecadienoic acid, a lipoxygenase pathway metabolite, which-through further enzymatic or spontaneous reactions-may lead to the appearance of trans-2-nonenal. The invention enables brewers to produce a beer devoid of detectable trans-2-nonenal-specific off flavors, even after prolonged storage of the beverage. | 08-06-2015 |
Birgitte Skadhauge, Birkerod DK
Patent application number | Description | Published |
---|---|---|
20090029000 | Barley for Production of Flavor-Stable Beverage - According to the invention, there is provided null-LOX-1 barley and plant products produced thereof, such as malt manufactured by using barley kernels defective in synthesis of the fatty acid-converting enzyme lipoxygenase-1. Said enzyme accounts for the principal activity related to conversion of linoleic acid into 9-hydroperoxy octadecadienoic acid, a lipoxygenase pathway metabolite, which-through further enzymatic or spontaneous reactions may lead to the appearance of trans-2-nonenal. The invention enables brewers to produce a beer devoid of detectable trans-2-nonenal-specific off flavors, even after prolonged storage of the beverage. | 01-29-2009 |
20110195151 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE - According to the invention, there is provided null-LOX-1 barley and plant products produced thereof, such as malt manufactured by using barley kernels defective in synthesis of the fatty acid-converting enzyme lipoxygenase-1. Said enzyme accounts for the principal activity related to conversion of linoleic acid into 9-hydroperoxy octadecadienoic acid, a lipoxygenase pathway metabolite, which-through further enzymatic or spontaneous reactions-may lead to the appearance of trans-2-nonenal. The invention enables brewers to produce a beer devoid of detectable trans-2-nonenal-specific off flavors, even after prolonged storage of the beverage. | 08-11-2011 |
20110293779 | BARLEY AND MALT-DERIVED BEVERAGES WITH LOW DMS LEVEL - According to the invention, there is provided barley-derived beverages characterized by notably reduced levels of both dimethyl sulfide (DMS) and/or its precursor S-methyl-L-methionine (SMM), or lacking said compounds. In addition, the invention relates to methods for producing the above-mentioned beverages—and also to barley plants useful in the preparation of such beverages, as well as other plant products prepared from said plants. Utilization of the invention clears the way for making improved production procedures of beverages with improved taste profiles, and promises also for notable reductions in the thermal energy input for production of beer. | 12-01-2011 |
20110318469 | Barley with reduced lipoxygenase activity and beverage prepared therefrom - According to the invention, there is provided barley with total loss of functional lipoxygenase (LOX)-1 and LOX-2 enzymes, and plant products produced thereof, such as malt manufactured by using barley kernels defective in the synthesis of the fatty acid-dioxygenating enzymes LOX-1 and LOX-2. Said enzymes account for the principal activities related to dioxygenation of linoleic acid into 9- and 13-hydroperoxy octadecadienoic acid, respectively. 9-Hydroperoxy octadecadienoic acid represents a LOX pathway metabolite, which—through further enzymatic or spontaneous reactions—may lead to the appearance of trans-2-nonenal (T2N). The invention enables brewers to produce a beer having insignificant levels of stale, T2N-specific off-flavors, even after prolonged storage of the beverage. | 12-29-2011 |
20130095207 | ENERGY SAVING BREWING METHOD - Barley based beverages are produced in large quantities, employing highly energy consuming methods, for example in the malting and brewhouse facilities for kiln drying and wort boiling operations, respectively. The present invention relates to energy saving methods for preparing barley based beverages, as well as to barley plants useful in such methods. In particular, the invention describes barley plants with combined traits of null-lipoxygenase-1 (null-LOX-1), null-lipoxygenase-2 (null-LOX-2) and null-S-adenosylmethionine:methionine S-methyltransferase in one plant, which is particularly useful for energy saving methods to prepare barley based beverages, such as beer. | 04-18-2013 |
Birgitte Stuer-Lauridsen, Virum DK
Patent application number | Description | Published |
---|---|---|
20080317903 | Bacteriophage Resistant Lactic Acid Bacteria - A lactic acid bacterium (LAB) wherein an YjaE protein is essentially inactive and the LAB thereby get improved resistance to bacteriophages, a starter culture composition comprising the lactic acid bacterium and use of this starter culture manufacturing a food or feed product. | 12-25-2008 |
20110223251 | BACTERIAL COMPOSITION - The present invention relates to a bacterial composition which has a long shelf-life, and a process for producing such compositions. The invention further relates to food products comprising the bacterial composition. | 09-15-2011 |
20150079058 | ANTIBIOTIC SENSITIVE BACILLUS STRAINS HAVING ANTIMICROBIAL EFFECT AGAINST E. COLI AND CLOSTRIDIUM PERFRINGENS AND HAVING HIGH SPORULATION CAPACITY | 03-19-2015 |
Birgitte Urs, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20080305986 | Multimers of Peptides - Described are compounds useful for trimerising chemical entities, methods of trimerising chemical entities, and trimerised entities. In one aspect, the entities are peptides. | 12-11-2008 |
Birgitte Ursø, Copenhagen O DK
Patent application number | Description | Published |
---|---|---|
20100056764 | Antibodies against human NKG2D and uses thereof - The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies. | 03-04-2010 |
Birgitte Willumsen, Bronshoj DK
Patent application number | Description | Published |
---|---|---|
20090306092 | METHOD FOR TREATING COGNITIVE DEFICITS - The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan- | 12-10-2009 |
20110178094 | Oral Formulation - The invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and to a composition comprising the compound. | 07-21-2011 |
20110207744 | Method for treating cognitive deficits - The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine. | 08-25-2011 |
Birgitte Wintherlund, Bagsvaerd DK
Patent application number | Description | Published |
---|---|---|
20090131510 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS - Disclosed herein are compounds of Formula I | 05-21-2009 |
Birgitte Winther Lund, Bagsvaerd DK
Patent application number | Description | Published |
---|---|---|
20090270449 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - Disclosed herein is a novel class of aminophenyl compounds having the structure: | 10-29-2009 |
20110046237 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS - Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof. | 02-24-2011 |